Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV

AIDS. 2022 Apr 1;36(5):691-695. doi: 10.1097/QAD.0000000000003161.


Objective: To evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people with HIV (PWH).

Methods: Participants were evaluated 4 weeks after the second dose of mRNA-1273 or BNT162b2 vaccine. Tolerability was evaluated with a specific adverse event questionnaire. Patient's sera were analysed using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin).

Results: One-hundred PWH were included, 75% of them men, with a mean age of 44 ± 11 years old, all receiving antiretroviral treatment and mostly with controlled viral loads (98% with HIV RNA <50 copies/ml) and 96% had >200 CD4+/μl. All patients seroconverted after vaccination (antibody concentration ≥33.8 binding antibody units [BAU]/ml). Only 3% of the patients had a low antibody concentration (<520 BAU/ml), whereas 67% of them had concentrations above the assay's detection range (>2080 BAU/ml). Fifty-six patients had local or systemic symptoms, with mild arthromyalgia being the most common systemic symptom. No severe adverse events were reported.

Conclusions: Vaccination with two doses of mRNA-1273 or BNT162b2 is well tolerated in PWH under effective antiretroviral treatment and it leads to a successful antibody response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral
  • BNT162 Vaccine / adverse effects
  • BNT162 Vaccine / therapeutic use
  • COVID-19 Vaccines / adverse effects
  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / prevention & control
  • Female
  • HIV Infections* / drug therapy
  • Humans
  • Immunogenicity, Vaccine
  • Male
  • Middle Aged
  • SARS-CoV-2


  • Antibodies, Viral
  • COVID-19 Vaccines
  • BNT162 Vaccine